Clinic
Baptist Health
Baptist Health was paid $3.69M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 15% of everything it billed.
33Billing provider infoBAPTIST HEALTH
HEBER SPRINGS, AR 72543
HEBER SPRINGS, AR 72543
33aNPI1609804822assigned 06/28/2006
33bProvider typeRehabilitation Clinic/Center
28Total paid$3.69M
24GClaims179,558
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Arkansas
Rank by total paid#13 of 27
Median peer was paid$3.03M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WELLS, TROY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,272 | $366K | |
| 2019 | 28,962 | $510K | |
| 2020 | 24,797 | $469K | |
| 2021 | 29,157 | $618K | |
| 2022 | 34,095 | $692K | |
| 2023 | 23,563 | $583K | |
| 2024incomplete | 17,712 | $452K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 15% | 11,855 | 9,835 | $548K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 11% | 2,940 | 2,709 | $388K |
| 70450 | Computed tomography, head or brain; without contrast material | 8.6% | 2,275 | 1,944 | $316K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.6% | 7,237 | 1,786 | $245K |
| 80048 | Basic metabolic panel (calcium, ionized) | 6.4% | 5,028 | 4,220 | $237K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.0% | 2,351 | 2,130 | $220K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.4% | 1,316 | 1,155 | $197K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 15,320 | 12,357 | $100K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 1,642 | 1,343 | $74K |
| 80050 | General health panel | 2.0% | 1,593 | 1,518 | $74K |
| 80076 | 1.9% | 2,016 | 1,773 | $71K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 788 | 705 | $71K |
146 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 2,877 | $51K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 7,781 | $45K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 2,436 | $41K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 4,136 | $40K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,955 | $36K |
| 84484 | <1% | 3,507 | $36K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,750 | $35K |
| 80061 | Lipid panel | <1% | 3,140 | $34K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,364 | $34K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,383 | $31K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 570 | $31K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 369 | $31K |
| 83880 | <1% | 1,674 | $30K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,372 | $30K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 586 | $28K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 75 | $27K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,727 | $27K |
| 83605 | <1% | 2,528 | $27K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,059 | $25K |
| 82550 | <1% | 2,929 | $23K | |
| 80305 | <1% | 1,726 | $22K | |
| 72100 | <1% | 524 | $19K | |
| 87088 | <1% | 2,472 | $19K | |
| 87040 | <1% | 2,427 | $19K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,062 | $19K |
| 83690 | <1% | 2,372 | $18K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,534 | $18K |
| 81025 | <1% | 1,851 | $18K | |
| 87631 | <1% | 261 | $18K | |
| 81001 | <1% | 4,873 | $16K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 387 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 135 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,538 | $12K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 107 | $12K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 319 | $12K |
| 85027 | <1% | 1,907 | $11K | |
| 82150 | <1% | 1,354 | $10K | |
| 99283 | Emergency room visit (moderate) | <1% | 903 | $10K |
| 82077 | <1% | 555 | $10K | |
| 83735 | <1% | 1,567 | $9K | |
| 99284 | Emergency room visit (serious) | <1% | 1,413 | $9K |
| 81003 | <1% | 4,245 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,885 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,223 | $7K |
| 87077 | <1% | 845 | $7K | |
| 97032 | <1% | 306 | $6K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 125 | $6K |
| 96376 | <1% | 231 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 876 | $6K |
| 80179 | <1% | 295 | $6K | |
| 73630 | <1% | 185 | $6K | |
| 85610 | <1% | 2,128 | $5K | |
| 80143 | <1% | 280 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,399 | $5K |
| 82962 | <1% | 595 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,058 | $5K |
| 82803 | <1% | 277 | $4K | |
| 80306 | <1% | 221 | $4K | |
| 97161 | <1% | 80 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $4K |
| 73560 | <1% | 137 | $4K | |
| 87186 | <1% | 798 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 147 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 18 | $3K |
| 85379 | <1% | 345 | $3K | |
| 73610 | <1% | 114 | $3K | |
| 97001 | <1% | 112 | $3K | |
| 87420 | <1% | 172 | $2K | |
| 82607 | <1% | 185 | $2K | |
| 71020 | <1% | 206 | $2K | |
| 82375 | <1% | 277 | $2K | |
| 72040 | <1% | 67 | $2K | |
| 74018 | <1% | 123 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $2K |
| 86803 | <1% | 135 | $2K | |
| 80320 | <1% | 106 | $2K | |
| 72131 | <1% | 14 | $2K | |
| 86900 | <1% | 31 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,312 | $1K |
| 80069 | <1% | 168 | $1K | |
| 82805 | <1% | 65 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 101 | $1K |
| 73110 | <1% | 27 | $1K | |
| 73030 | <1% | 63 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 21 | $997.65 |
| 85730 | <1% | 267 | $928.85 | |
| 73562 | <1% | 12 | $861.21 | |
| 80329 | <1% | 44 | $792.66 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 603 | $774.79 |
| 99285 | Emergency room visit (most serious) | <1% | 52 | $750.50 |
| 82248 | <1% | 152 | $747.20 | |
| 82947 | <1% | 158 | $660.51 | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $635.80 |
| 85007 | <1% | 233 | $609.29 | |
| 74019 | <1% | 35 | $599.85 | |
| 71010 | <1% | 102 | $585.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 973 | $573.05 |
| 84450 | <1% | 127 | $558.78 | |
| 84460 | <1% | 122 | $542.19 | |
| 74022 | <1% | 26 | $518.27 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,060 | $511.19 |
| 36600 | <1% | 292 | $488.56 | |
| 73502 | <1% | 15 | $460.70 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 174 | $450.29 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,456 | $428.27 |
| 84703 | <1% | 27 | $358.20 | |
| 86901 | <1% | 31 | $357.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 21 | $342.27 |
| 85055 | <1% | 26 | $333.02 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $280.12 |
| 94760 | <1% | 25 | $280.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 31 | $278.11 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,888 | $238.17 |
| 82247 | <1% | 46 | $216.50 | |
| 82728 | <1% | 28 | $211.68 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 459 | $198.01 |
| 87807 | <1% | 14 | $187.34 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 75 | $183.68 |
| 73130 | <1% | 16 | $183.54 | |
| 87400 | <1% | 14 | $149.44 | |
| 84075 | <1% | 32 | $141.86 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,653 | $126.00 |
| 86140 | <1% | 13 | $118.53 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $115.22 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 200 | $109.05 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 340 | $100.22 |
| 86780 | <1% | 17 | $93.20 | |
| 87070 | <1% | 23 | $77.12 | |
| 87340 | <1% | 14 | $70.32 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 80 | $64.04 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 21 | $60.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 163 | $50.65 |
| 86762 | <1% | 14 | $48.99 | |
| 87205 | <1% | 18 | $32.15 | |
| A9270 | Non-covered item or service | <1% | 2,585 | $25.45 |
| 82746 | <1% | 17 | $21.00 | |
| 81015 | <1% | 36 | $20.77 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,179 | $13.77 |
| 85652 | <1% | 20 | $11.55 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 72 | $6.21 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 422 | $1.17 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16 | $0.60 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 18 | $0.08 |
| 0353U | 0% | 34 | $0.00 | |
| 86850 | 0% | 27 | $0.00 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELLS, TROY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Baptist Health Regional Hospitals | Fort Smith, AR | $17.49M |
| Baptist Health | Little Rock, AR | $16.48M |
| Baptist Health | North Little Rock, AR | $14.02M |
| Baptist Health | Arkadelphia, AR | $4.82M |
| Conway Community Services | Conway, AR | $4.12M |
| Baptist Health Hospitals | Stuttgart, AR | $2.97M |
| Baptist Health | Little Rock, AR | $2.93M |
| Baptist Health | Malvern, AR | $2.68M |
| Baptist Health Regional Hospitals | Van Buren, AR | $2.46M |
| Baptist Health | Little Rock, AR | $1.83M |
| Baptist Health | Arkadelphia, AR | $1.51M |
| Baptist Health Hospitals | Stuttgart, AR | $901K |
| Baptist Health | Little Rock, AR | $780K |
| Baptist Health | North Little Rock, AR | $411K |
| Baptist Health | Monticello, AR | $367K |
| Baptist Health | Conway, AR | $142K |
| Baptist Health | Little Rock, AR | $88K |
| Baptist Health | Prescott, AR | $33K |
| Baptist Health | Malvern, AR | $31K |
| Baptist Health | Heber Springs, AR | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.